WebFeb 22, 2024 · Press Releases. "Extra-Strength" Formulation of Jeuveau® Demonstrates Effects Lasting 26 Weeks in Interim Phase II Data Results, Representing Prolonged 6 … WebMar 23, 2024 · Pro Forma Cash Position of $57 Million at December 31, 20241 NEWPORT BEACH, Calif., March 23, 2024 (GLOBE NEWSWIRE) -- Evolus, Inc. (Nasdaq: EOLS), a performance beauty company with a customer ...
EOLS - Evolus Inc Stock News - NASDAQ Morningstar
WebApr 10, 2024 · In 2024, Evolus's revenue was $148.62 million, an increase of 49.10% compared to the previous year's $99.67 million. Losses were -$74.41 million, 59.0% … WebJan 28, 2024 · Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products, today presented interim data from its Phase II clinical study evaluating an "extra-strength" formulation for extended duration of Jeuveau ® (prabotulinumtoxinA-xvfs), its flagship neurotoxin … shipbuilding in uae
Evolus Strengthens Balance Sheet Through a $25.5 Million Cash …
WebFeb 26, 2024 · Also announced today, Michael Mazen Jafar will depart Evolus on February 26 to lead a health technology organization. Michael previously led the marketing and sales organization as Chief ... WebMay 18, 2024 · Evolus, Inc., today celebrates the three-year anniversary of the launch of its flagship neurotoxin product, Jeuveau® (prabotulinumtoxinA-xvfs). WebJul 3, 2024 · As you might expect, Evolus' stock price cratered on the news, ... Why Evolus Stock Dived by Almost 19% Today. Evolus, Inc. (EOLS) Q1 2024 Earnings Call … shipbuilding in the usa